What's Happening?
Biogen and Ionis have unveiled clinical results for their tau-targeting Alzheimer's drug candidate, diranersen, at the Alzheimer's Association International Conference in London. The phase 2 CELIA study demonstrated that diranersen slowed cognitive decline
by 26% compared to placebo over 76 weeks in patients with early Alzheimer's. This efficacy is comparable to existing amyloid-targeting drugs like Eisai/Biogen's Leqembi and Eli Lilly's Kisunla. Diranersen aims to reduce both intracellular and extracellular tau, unlike other drugs that target only extracellular tau. Despite promising results, shares of Biogen and Ionis fell due to concerns over the lack of a dose-response relationship in the trial data. The strongest cognitive response was observed with a 60 mg dose administered intrathecally every six months, while higher doses showed less efficacy. Biogen and Ionis plan to proceed with a phase 3 program for diranersen next year, with potential results expected by the end of the decade.
Why It's Important?
The development of diranersen represents a significant advancement in Alzheimer's treatment, offering a potential complementary approach to existing amyloid-targeting therapies. The ability to target tau proteins, which are implicated in the progression of Alzheimer's, could enhance treatment efficacy when combined with amyloid drugs. This could lead to improved outcomes for patients suffering from Alzheimer's, a disease that affects millions globally. However, the lack of a clear dose-response relationship raises questions about the drug's optimal dosing strategy, which could impact its commercial viability and acceptance in the medical community. The dip in Biogen and Ionis shares reflects investor uncertainty regarding the drug's future prospects and the challenges of demonstrating consistent efficacy across different doses.
What's Next?
Biogen and Ionis are preparing to launch a phase 3 clinical trial for diranersen, aiming to further investigate its efficacy and safety in a larger patient population. This trial is expected to begin next year, with results anticipated by the end of the decade. The companies will need to address the dose-response concerns to optimize the drug's therapeutic potential. Success in the phase 3 trial could lead to regulatory approval and commercialization, providing a new treatment option for Alzheimer's patients. The outcome of these trials will be closely watched by stakeholders, including healthcare providers, patients, and investors, as it could influence future research directions and investment in Alzheimer's therapies.
